How Milk Proteins and Their Bioactive Peptides May Help Prevent and Manage Type 2 Diabetes | Research

The takeaway

Milk proteins lower postprandial blood glucose by releasing bioactive peptides and amino acids that slow stomach emptying and enhance incretin and insulin responses — mechanisms that parallel the action of GLP-1 drugs.

Milk peptides enhance the same incretin pathway as GLP-1 drugs
Bioactive peptides released during milk protein digestion boost GLP-1 and GIP incretin hormones — the same mechanism exploited by semaglutide, liraglutide, and tirzepatide

What the researchers found

The review establishes three primary mechanisms by which milk protein-derived peptides lower postprandial glucose. First, they delay gastric emptying, slowing the rate at which carbohydrates enter the small intestine. Second, they enhance incretin hormone responses — particularly GLP-1 and GIP — which are the same hormones mimicked by blockbuster diabetes drugs like semaglutide. Third, they directly increase postprandial insulin secretion.

These effects have been demonstrated in both healthy subjects and patients with type 2 diabetes. The bioactive peptides released during milk protein digestion are the proposed mediators, creating a physiological milieu that naturally amplifies the body's blood sugar control mechanisms.

Why it matters

With type 2 diabetes projected to affect over 1.3 billion people by 2050, dietary interventions that can complement or even partially replace pharmaceutical approaches are urgently needed. Milk proteins are safe, widely available, and inexpensive compared to GLP-1 drugs. The finding that they work partly through the same incretin pathway targeted by semaglutide and tirzepatide suggests a natural, food-based approach to blood sugar management that could be accessible to populations without access to expensive peptide medications.

How the study worked

This is a narrative review summarizing evidence from epidemiological studies linking dairy consumption to diabetes risk, clinical trials of milk protein supplementation on postprandial glucose and insulin responses, and mechanistic studies identifying bioactive peptides and their targets.

What this study cannot tell us

As a narrative review, the paper may not comprehensively capture all available evidence or assess studies for bias. The exact contribution of milk proteins versus other dairy nutrients (calcium, vitamin D, fat) to diabetes risk reduction is difficult to disentangle. The bioavailability and potency of milk-derived bioactive peptides in vivo remain uncertain. Individual variation in milk protein digestion (affected by lactose tolerance, gut microbiome, and proteolytic enzyme activity) could significantly affect outcomes. The review does not quantify the magnitude of glucose-lowering effects compared to pharmaceutical interventions.

How to read the evidence

This is a narrative review synthesizing epidemiological, clinical, and mechanistic evidence. While individual studies cited include randomized controlled trials, the review itself is not a systematic review or meta-analysis, limiting the strength of its overall conclusions.

When this study was published

Published in 2019, this review predates the widespread adoption of GLP-1 drugs for obesity but accurately identifies the incretin pathway as central to milk proteins' metabolic benefits. The relevance has only increased as GLP-1 drugs have become more prominent.

The bigger picture

This review sits at the intersection of nutritional science and peptide pharmacology. The incretin-enhancing effect of milk-derived peptides parallels the mechanism of the most successful diabetes and obesity drugs in history (GLP-1 receptor agonists). While food-derived peptides are far less potent than pharmaceutical GLP-1 drugs, they represent a complementary approach — particularly for diabetes prevention in at-risk populations. The concept of 'food as medicine' gains scientific credibility when specific molecular mechanisms, like incretin enhancement, can be identified and measured.

Questions still open

Could standardized milk protein supplements be developed as adjunctive therapy for type 2 diabetes, and would they be cost-effective compared to medication?
Which specific milk-derived peptides are most responsible for the incretin-enhancing effect, and could they be isolated and concentrated?
Does the type of milk protein matter — do whey and casein produce different bioactive peptide profiles with different effects on glucose metabolism?

Common questions

Can drinking milk really help with diabetes?

Evidence suggests that dairy consumption, particularly milk proteins, can help lower blood sugar after meals. When you digest milk proteins, they break down into small peptides and amino acids that slow stomach emptying, boost hormones that trigger insulin release (the same hormones mimicked by drugs like Ozempic), and directly enhance insulin secretion. While this won't replace diabetes medication, including dairy protein in meals may be a helpful dietary strategy.

Is whey protein or casein better for blood sugar control?

Both have beneficial effects, but they work differently. Whey protein is digested quickly and produces a rapid insulin response, while casein is digested more slowly, providing a sustained effect. Some research suggests whey protein may be more effective for lowering postprandial glucose spikes when consumed before or with a carbohydrate-rich meal. The bioactive peptides released during digestion differ between the two proteins.

Read the original research

Milk in the prevention and management of type 2 diabetes: The potential role of milk proteins.

Diabetes/metabolism research and reviews, 35(8), e3187

View on PubMed ↗Publisher’s paper ↗

Citation

Hidayat, Khemayanto; Du, Xuan; Shi, Bi-Min. (2019). Milk in the prevention and management of type 2 diabetes: The potential role of milk proteins.. Diabetes/metabolism research and reviews, 35(8), e3187. https://doi.org/10.1002/dmrr.3187